Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
2.6
Journals
Current Oncology
Special Issues
Chemotherapy and Novel Treatment Combinations in Breast Cancer
share announcement

Chemotherapy and Novel Treatment Combinations in Breast Cancer

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 11396

Special Issue Editor

Dr. Eleni Timotheadou

E-Mail Website
Guest Editor
Medical Oncologist, Medical Oncology Clinic Aristotle University of Thessaloniki, Papageorgiou Hospital, 56429 Thessaloniki, Greece
Interests: breast cancer; gynecologic cancer; genetic counseling; translational research
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Despite the many improvements in its diagnosis and treatment, breast cancer remains a major public health issue for most countries, particularly in the Western world. The development of new treatment combinations and the introduction of new families of active agents, together with the potential identification of more homogeneous subgroups of patients based on precision medicine data, has created a novel research area attracting the interest of both scientists and patients, in the pursuit of more effective treatments and a better understanding of the disease itself. We are pleased to invite submissions focusing on current trends in the treatment of all stages of breast cancer, including chemotherapy and novel agents.We welcome manuscripts in the following formats:·      

  • Original research;
  • Basic research;   
  • Translational and clinical research; ·      
  • Review articles; ·      
  • Short communications; ·      
  • Case reports; 

We are looking forward to your contributions.

Dr. Eleni Timotheadou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • adjuvant
  • neoadjuvant
  • advanced
  • HER2-positive
  • triple-negative
  • BRCA-mutations
  • CDK4/6 inhibitors
  • endocrine therapy

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 2305 KiB  
Article
Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group
by Stefania Kokkali, Emmanouil Saloustros, Dimitra Stefanou, Paris Makrantonakis, Nikolaos Kentepozidis, Ioannis Boukovinas, Nikolaos Xenidis, Panagiotis Katsaounis, Alexandros Ardavanis, Nikolaos Ziras, Athina Christopoulou, George Rigas, Kostas Kalbakis, Nikolaos Vardakis, Christos Emmanouilides, Ilias Athanasiadis, Athanassios Anagnostopoulos, Dora Hatzidaki, Efthimios Prinarakis, Foteini Simopoulou, Athanasios Kotsakis and Vassilis Georgouliasadd Show full author list remove Hide full author list
Curr. Oncol. 2022, 29(2), 1237-1251; https://doi.org/10.3390/curroncol29020105 - 17 Feb 2022
Cited by 1 | Viewed by 1949
Abstract
Front-line bevacizumab (BEV) in combination with taxanes offers benefit in progression-free survival (PFS) in metastatic breast cancer (mBC). The medical records of mBC patients, treated with front-line BEV-based chemotherapy, were retrospectively reviewed in order to generate real life safety and efficacy data. Patients [...] Read more.
Front-line bevacizumab (BEV) in combination with taxanes offers benefit in progression-free survival (PFS) in metastatic breast cancer (mBC). The medical records of mBC patients, treated with front-line BEV-based chemotherapy, were retrospectively reviewed in order to generate real life safety and efficacy data. Patients with human epidermal growth factor receptor 2 (HER2)-negative mBC treated with front-line BEV in combination with chemotherapy were eligible. Maintenance therapy with BEV and/or hormonal agents was at the physicians’ discretion. Among the 387 included patients, the most common adverse events were anemia (61.9%, mainly grade 1), grade 3/4 neutropenia (16.5%), grade 1/2 fatigue (22.3%), and grade 1/2 neuropathy (19.6%). Dose reductions were required in 164 cycles (7.1%) and toxicity led to treatment discontinuation in 21 patients (5.4%). The median PFS and the median overall survival (OS) were 13.3 (95% CI: 11.7–14.8) and 32.3 months (95% CI: 27.7–36.9), respectively. Maintenance therapy, with hormonal agents (ET) and/or BEV, was associated with longer OS versus no maintenance therapy (47.2 versus 23.6 months; p < 0.001) in patients with hormone receptor (HR)-positive disease and BEV maintenance offered longer OS versus no maintenance in patients with HR-negative disease (52.8 versus 23.3; p = 0.023). These real-life data show that front-line BEV-based chemotherapy in HER2-negative mBC patients is an effective treatment with an acceptable toxicity profile. The potential benefit of maintenance treatment, especially ET, is important and warrants further research. Full article
(This article belongs to the Special Issue Chemotherapy and Novel Treatment Combinations in Breast Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 763 KiB  
Review
Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
by Mehrnoosh Pauls, Stephen Chia and Nathalie LeVasseur
Curr. Oncol. 2022, 29(7), 4748-4767; https://doi.org/10.3390/curroncol29070377 - 07 Jul 2022
Cited by 9 | Viewed by 5908
Abstract
Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care [...] Read more.
Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC. Full article
(This article belongs to the Special Issue Chemotherapy and Novel Treatment Combinations in Breast Cancer)
►▼ Show Figures

Figure 1

13 pages, 277 KiB  
Review
The Role of the 21-Gene Recurrence Score® Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience
by Mariya Yordanova and Saima Hassan
Curr. Oncol. 2022, 29(3), 2008-2020; https://doi.org/10.3390/curroncol29030163 - 16 Mar 2022
Cited by 8 | Viewed by 2758
Abstract
The management of patients with hormone receptor-positive breast cancer has changed dramatically with use of the 21-gene Recurrence Score® (RS) Assay. While the utility of the assay was initially demonstrated among node-negative patients, recent studies have also demonstrated the assay’s prognostic and [...] Read more.
The management of patients with hormone receptor-positive breast cancer has changed dramatically with use of the 21-gene Recurrence Score® (RS) Assay. While the utility of the assay was initially demonstrated among node-negative patients, recent studies have also demonstrated the assay’s prognostic and predictive value in node-positive patients. In Canada, the RS assay is reimbursed by provincial health insurance plans, but not all provinces have approved the use of the assay for patients with node-positive disease. Here, we provide an overview of the clinical factors that influence physician recommendation of the RS assay and, alternatively, the impact of the RS assay on patient treatment decisions in Canada. We performed a comprehensive review of the impact of the assay upon physician treatment decisions and cost in node-positive breast cancer patients within Canada and other countries. Furthermore, we evaluated biomarkers that can predict the RS result, in addition to other genomic assays that predict recurrence risk among node-positive patients. Overall, the 21-gene RS assay was shown to be a cost-effective tool that significantly reduced the use of chemotherapy in node-positive breast cancer patients in Canada. Full article
(This article belongs to the Special Issue Chemotherapy and Novel Treatment Combinations in Breast Cancer)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop